Safety and tolerability of once-daily tiotropium Respimat<sup>®sup> as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis
详细信息 查看全文
- 作者：Ronald Dahl<sup>asup><sup> ; sup><sup>ronald.dahl2@rsyd.dk" class="auth_mail" title="E-mail the corresponding authorsup> ; Michael Engel<sup>bsup> ; Daniel Dusser<sup>csup> ; David Halpin<sup>dsup> ; Huib A.M. Kerstjens<sup>esup> ; Liliana Zaremba-Pechmann<sup>fsup> ; Petra Moroni-Zentgraf<sup>bsup><sup> ; sup><sup>isup> ; William W. Busse<sup>gsup> ; Eric D. Bateman<sup>hsup>
- 关键词：Asthma ; Respimat® ; Safety ; Tiotropium ; Tolerability
- 刊名：Respiratory Medicine
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：118
- 期：Complete
- 页码：102-111
- 全文大小：259 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
Tiotropium Respimat<sup>®sup> demonstrated safety and tolerability comparable with placebo.
- class="label">•
Incidence of adverse events and serious adverse events was similar between groups.
- class="label">•
Overall incidence of dry mouth, common with anticholinergic use, was low.
- class="label">•
Low number of cardiac disorder adverse events, comparable between groups.
- class="label">•
No deaths occurred during any of the trials.